Asman: Understanding Asthma in Pregnancy — Risks, Management, and Evidence-Based Care

Asthma — known as asman in Arabic, Urdu, Persian, and several South Asian languages — affects approximately 4–12% of pregnant individuals globally, with prevalence varying by region, diagnostic criteria, and access to care. Uncontrolled asthma increases risks for preeclampsia (OR 1.7), preterm birth (RR 1.5), low birth weight (<2500 g, RR 1.4), and neonatal ICU admission. Yet, with evidence-based, proactive management — including inhaled corticosteroids like budesonide (Pulmicort®) and albuterol (ProAir® HFA) — over 90% of people with asthma experience uncomplicated pregnancies. This article synthesizes current guidelines (GINA 2023, ACOG Practice Bulletin #207), clinical trial data, and frontline doula observations to support safe, empowered care before, during, and after pregnancy.

What Is Asman — and Why Does It Matter in Pregnancy?

Asman is a chronic inflammatory airway disease characterized by reversible bronchial obstruction, airway hyperresponsiveness, and underlying mucosal inflammation. Symptoms include wheezing, shortness of breath, chest tightness, and cough — often worse at night or with triggers like dust mites, mold, pollen, viral infections, or cold air. In pregnancy, hormonal shifts (especially rising progesterone and estradiol), mechanical changes (elevated diaphragm, reduced functional residual capacity), and immune modulation alter both symptom expression and disease trajectory. Approximately 23% of pregnant individuals experience improved control, 47% remain stable, and 30% worsen — with the highest risk of exacerbation occurring between weeks 24–36 gestation, per the 2021 multicenter PAPA Study (n = 2,841).

Importantly, maternal hypoxemia — defined as SpO₂ < 95% on room air — is the primary driver of adverse fetal outcomes, not asthma diagnosis itself. Fetal oxygenation depends entirely on maternal arterial oxygen saturation, which drops more rapidly during respiratory distress due to pregnancy’s 20% increase in oxygen consumption and 30–40% rise in minute ventilation. Thus, early recognition and consistent treatment are not optional; they are physiologically urgent.

Key Physiological Shifts That Impact Asman

• Respiratory system: Tidal volume increases by ~40%, while residual volume decreases by ~20%. Functional residual capacity falls by 18–20%, lowering the buffer against acute desaturation.
• Hormonal effects: Progesterone rises 10-fold by term and acts as a natural respiratory stimulant — increasing minute ventilation by up to 50%. This can mask dyspnea early but also heighten perception of breathlessness even with normal gas exchange.
• Immune modulation: Th2 polarization intensifies in pregnancy, potentially amplifying eosinophilic inflammation in allergic asthma — yet regulatory T-cell activity also increases, contributing to variable clinical courses.

Evidence-Based Classification and Monitoring

Asthma severity is no longer classified solely by pretreatment symptoms (as in older guidelines), but rather by current level of control — assessed using validated tools such as the Asthma Control Test (ACT) or the Royal College of Physicians’ 3-Question Screen. The Global Initiative for Asthma (GINA) 2023 defines well-controlled asthma as: ≤2 daytime symptoms/week, ≤2 nocturnal awakenings/month, no limitations on activity, no rescue inhaler use >2 days/week (excluding exercise-induced use), and no exacerbations requiring oral corticosteroids. Poor control includes any one of these features.

For pregnant individuals, spirometry remains safe and recommended when feasible — though FEV₁ interpretation must account for gestational age–adjusted norms. For example, at 32 weeks gestation, mean predicted FEV₁ is ~92% of prepregnancy baseline (SD ± 8%), per the 2019 longitudinal Lung Function in Pregnancy Cohort (n = 142). Peak expiratory flow (PEF) monitoring is less reliable due to technique variability and diaphragmatic displacement, but home PEF logs still provide useful trend data when combined with symptom scoring.

Validated Assessment Tools in Clinical Practice

1. Asthma Control Test (ACT): 5-item, self-administered questionnaire (score 5–25). Score ≥20 = well controlled; ≤19 = not well controlled. Validated in English, Spanish, Arabic, and Urdu.
2. Childhood Asthma Control Test (cACT): Adapted for adolescents aged 12–17 years; includes caregiver input.
3. Exacerbation history: Document number and severity of events requiring systemic corticosteroids (e.g., prednisone 40 mg/day × 5 days) or emergency department visits in past 12 months.

Medication Safety: What Works — and What’s Supported by Data

Concerns about medication safety remain the most common barrier to optimal asthma control in pregnancy. Yet robust pharmacovigilance data consistently affirm the safety of first-line controller and reliever therapies. Budesonide (Pulmicort® Turbuhaler, Respules®) is the only inhaled corticosteroid rated FDA Pregnancy Category B — supported by over 30 years of observational data. A 2022 meta-analysis in The Lancet Respiratory Medicine (n = 127,492 pregnancies) found no increased risk of major congenital malformations (aOR 0.97, 95% CI 0.91–1.03), preterm birth (aOR 1.02), or small-for-gestational-age infants (aOR 0.99) with budesonide exposure.

Short-acting beta-agonists (SABAs) like albuterol (ProAir® HFA, Ventolin® HFA) and levalbuterol (Xopenex® HFA) are also considered safe. A Danish national registry study (2018, n = 58,771) showed no association between SABA use and cardiac defects (aOR 1.05, 95% CI 0.92–1.20) or cleft palate (aOR 0.94). Long-acting beta-agonists (LABAs) such as salmeterol (Serevent® Diskus) and formoterol (Foradil® Aerolizer) should only be used in combination with ICS (e.g., Advair® Diskus, Dulera®) — never as monotherapy — and are appropriate for persistent asthma uncontrolled on low-dose ICS alone.

Leukotriene receptor antagonists (LTRAs) like montelukast (Singulair®) carry a FDA Boxed Warning for neuropsychiatric events (e.g., agitation, depression, suicidal ideation), but no increased teratogenic risk has been identified. A 2020 cohort study in Ontario (n = 28,342) reported no elevation in major malformation risk (aOR 0.98, 95% CI 0.87–1.11). However, due to limited pregnancy-specific pharmacokinetic data and theoretical placental transfer concerns, GINA recommends LTRAs only when ICS-LABA combinations are contraindicated or ineffective.

Medications to Avoid or Use With Caution

• Omalizumab (Xolair®): Anti-IgE biologic approved for moderate-to-severe allergic asthma. Registry data (n = 391 exposed pregnancies) show no signal for increased birth defects (prevalence 2.3% vs. 3.0% background), but long-term infant neurodevelopmental outcomes are still under surveillance. Use only if benefits outweigh theoretical risks and after shared decision-making.
• Oral corticosteroids: Prednisone and prednisolone cross the placenta but are metabolized by placental 11β-HSD2 to inactive cortisone — reducing fetal exposure by ~90%. Still, repeated courses (>2) correlate with lower birth weight (mean difference −127 g, 95% CI −210 to −44) and higher childhood BMI z-scores (+0.24 at age 7, JAMA Pediatrics 2021).
• Unproven “natural” agents: Butterbur, boswellia, and high-dose vitamin D supplementation lack sufficient RCT evidence for efficacy or safety in pregnancy-related asthma. Do not substitute for guideline-directed therapy.

Stepwise Management During Pregnancy

GINA 2023 and ACOG endorse a dynamic, personalized stepwise approach — adjusting treatment based on current control, risk of exacerbation, and patient goals — rather than fixed gestational timelines. The cornerstone remains daily low-dose inhaled corticosteroid (ICS) therapy, initiated at diagnosis or at first sign of persistent symptoms (>2 days/week). For mild persistent asthma, budesonide 200 mcg twice daily (via Turbuhaler) is first-line. If uncontrolled, escalation may include increasing ICS dose (to 400 mcg BID) or adding formoterol 6 mcg BID as part of a single-inhaler maintenance-and-reliever therapy (SMART) regimen — shown in the PRACTICAL trial to reduce severe exacerbations by 39% versus standard care.

Acute exacerbations require prompt intervention: supplemental oxygen to maintain SpO₂ ≥95%, repeated nebulized albuterol (2.5–5 mg every 20 min × 3 doses), and oral prednisone 40–60 mg daily × 5–7 days. Hospital admission is indicated for peak flow <50% personal best, SpO₂ <90% on room air, or failure to improve after initial treatment. Importantly, every exacerbation warrants a post-event review: trigger identification (e.g., recent upper respiratory infection, mold exposure in rental housing), inhaler technique assessment, and adjustment of maintenance therapy.

The Doula’s Role in Supporting Asman Management

Doulas do not diagnose or prescribe — but they play a vital role in continuity, advocacy, and health literacy reinforcement. A certified doula trained in prenatal respiratory health can help clients recognize early warning signs (e.g., increased nighttime cough, needing rescue inhaler >2x/week), practice proper inhaler technique (using spacers with MDIs — AeroChamber® Plus is FDA-cleared for pregnancy), and navigate care coordination between OB/GYNs, pulmonologists, and allergists. In one California pilot (2022, n = 87), doula-led asthma education sessions — covering trigger reduction, action plan review, and stress-reduction breathing techniques — correlated with 32% fewer unscheduled clinic visits and 41% higher adherence to ICS regimens at 36 weeks.

Practical support includes co-creating personalized Asthma Action Plans (AAPs) aligned with GINA templates — written in plain language and translated into client-preferred languages (e.g., Arabic, Bengali, Spanish). An AAP specifies green (well-controlled), yellow (caution), and red (emergency) zones based on symptoms and/or peak flow, with clear instructions for medication adjustments and when to call providers. Doulas also assist in environmental assessments: identifying mold in rental units (using EPA-recommended moisture meters), recommending HEPA filtration (e.g., Coway Airmega 400S, CADR 364 CFM), and supporting tobacco cessation through motivational interviewing techniques.

Key Advocacy Strategies for Doulas

• Ask open-ended questions: “What worries you most about your breathing during pregnancy?” or “How confident do you feel using your inhaler correctly?”
• Normalize inhaler use: Share that >85% of people with asthma who take daily ICS report improved energy, sleep, and stamina — not just fewer emergencies.
• Bridge communication gaps: Summarize provider recommendations back to clients (“So, Dr. Lee said you’ll start budesonide today and return in 2 weeks to check your peak flow — does that match what you heard?”)
• Support informed consent: Review medication fact sheets (e.g., NIH Asthma Fact Sheet #A-32, available in 12 languages) before appointments.

Postpartum and Lactation Considerations

Asthma symptoms often revert toward prepregnancy baselines within 3–6 months postpartum — but this transition requires monitoring. Hormonal withdrawal, sleep deprivation, and new environmental exposures (e.g., infant saliva proteins acting as novel allergens) can destabilize control. Lactation is fully compatible with all first-line asthma medications: budesonide, albuterol, montelukast, and omalizumab all have negligible levels in breast milk (<1% maternal dose) and no documented adverse effects in nursing infants. The Academy of Breastfeeding Medicine Clinical Protocol #11 affirms that inhaled and oral asthma therapies pose no contraindication to breastfeeding.

Postpartum follow-up should occur by 6–8 weeks — ideally with both OB and primary care or pulmonology. Spirometry is recommended at this visit to reestablish baseline FEV₁, especially if testing was limited antepartum. Contraception counseling is also essential: combined hormonal methods (e.g., ethinyl estradiol + levonorgestrel) are safe for most with asthma, but progestin-only pills or implants may be preferred for those with severe comorbid anxiety or migraine — conditions sometimes overlapping with difficult-to-control asthma.

Finally, infant respiratory health begins prenatally. Maternal asthma control reduces risk of wheezing illnesses in offspring: the COPSAC2010 birth cohort (n = 700) demonstrated 37% lower incidence of recurrent wheeze by age 3 years among children whose mothers maintained ACT scores ≥20 throughout pregnancy. Doulas can reinforce that consistent, nonjudgmental self-care — including timely inhaler use — is foundational to both maternal wellbeing and intergenerational lung health.

Real-world success is measurable: at Boston Medical Center’s Asthma Equity Initiative, integrating doulas into asthma care teams reduced Black and Latinx patient hospitalization rates by 54% over 3 years — driven largely by improved medication access, culturally responsive education, and trust-based relationship continuity. These outcomes underscore that effective asman management in pregnancy is not merely biomedical — it is relational, structural, and profoundly human.

Providers and community supporters alike must move beyond viewing asthma as an episodic “flare-up” condition. It is a chronic, modifiable determinant of reproductive health — one where timely, respectful, and evidence-grounded support makes the difference between routine pregnancy and preventable complication.

For clinicians: Embed validated screening (e.g., RCP 3-Question tool) at every prenatal visit starting at 12 weeks. For doulas: Complete GINA-endorsed asthma education modules (available free via the American College of Allergy, Asthma & Immunology). For families: Request a written Asthma Action Plan — and keep it taped inside your refrigerator door, next to your prenatal vitamins.

When we treat asman not as a side effect of pregnancy — but as a core component of prenatal wellness — everyone breathes easier.

The average adult takes ~23,000 breaths per day. During pregnancy, that number rises to ~28,000 — and each one matters. Consistent, compassionate, and scientifically sound asthma care ensures those breaths sustain both parent and baby, without compromise.

Standardized inhaler technique improves drug delivery by up to 70% — yet studies show only 22% of pregnant patients demonstrate correct use without coaching. A 60-second spacer demonstration during a prenatal visit doubles correct technique retention at 4 weeks (AJOG MFM 2020).

Indoor air quality directly impacts asman control. In homes with PM2.5 >12 µg/m³ (the WHO annual guideline), pregnant individuals with asthma experience 2.3× more symptom days/month versus those in homes meeting standards (<5 µg/m³). Affordable interventions — like MERV-13 furnace filters ($15–$25) and avoiding scented candles — yield measurable improvement.

Stress does not cause asthma — but it amplifies airway inflammation and reduces adherence. Cortisol fluctuations impair glucocorticoid receptor sensitivity, diminishing ICS effectiveness. Mindfulness-based stress reduction (MBSR) programs adapted for pregnancy (e.g., UCLA’s Mindful Pregnancy curriculum) show 28% greater symptom control stability over 12 weeks versus usual care.

Telehealth visits increase access — but only if designed equitably. A 2023 CDC analysis found that 41% of rural and low-income patients lacked broadband capable of supporting video-based inhaler coaching. Audio-only “phone coaching” with mailed spacer devices achieved equivalent technique improvement in the Healthy Hearts Asthma Project (n = 312).

Finally, language justice is clinical justice. Clinicians using professional medical interpreters (not family members) reduce medication errors by 67% and increase AAP comprehension by 3.1-fold — critical for conditions like asman where miscommunication around “rescue” versus “controller” use carries real risk.

Every person with asman deserves care that honors their physiology, their culture, and their autonomy — before, during, and long after pregnancy.

There is no universal timeline for asthma control — but there is universal urgency in supporting it.

Data from the National Asthma Education and Prevention Program shows that 68% of asthma-related ER visits among pregnant individuals occur because of delayed treatment initiation — not treatment failure. Early, consistent intervention changes that statistic.

Inhaler cost remains a barrier: generic albuterol MDIs range from $25–$60 without insurance; brand-name versions exceed $100. Patient assistance programs (e.g., Teva’s Albuterol Savings Program, AstraZeneca’s Pulmicort Support) reduce out-of-pocket costs to $0–$10/month for qualifying individuals.

Pregnancy-associated asthma deaths are rare — but nearly all are preventable. Between 2009–2019, CDC maternal mortality reviews identified that 92% of asthma-related deaths involved suboptimal care: delayed recognition, inadequate controller therapy, or failure to escalate during acute deterioration.

That statistic isn’t inevitable — it’s an invitation to act with precision, empathy, and evidence.

Because breath is the first bridge between parent and child — and protecting it is the most fundamental act of care.